Wholly Owned Pipeline
PureTech's Wholly Owned Programs are designed to harness immunological and lymphatic system mechanisms for the treatment of lung dysfunction, oncology, lymphatic, neurological and neuropsychological disorders.
Wholly Owned Pipeline
2 | IPF & other progressive fibrosing ILDs | 140–250K U.S. (PF-ILD including IPF) |
Product candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., idiopathic pulmonary fibrosis (IPF), unclassifiable interstitial lung diseases (uILDs), Long COVID respiratory complications and related sequelae) and lymphedema.
2 | Long COVID respiratory complications & related sequelae |
Product candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., idiopathic pulmonary fibrosis (IPF), unclassifiable interstitial lung diseases (uILDs), Long COVID respiratory complications and related sequelae) and lymphedema.
2 | Lymphatic flow disorders, incl. lymphedema | ~1M U.S. |
Product candidate being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow, including lung dysfunction conditions (e.g., idiopathic pulmonary fibrosis (IPF), unclassifiable interstitial lung diseases (uILDs), Long COVID respiratory complications and related sequelae) and lymphedema.
1 | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-200 is a monoclonal antibody targeting a foundational immunosuppressive protein, galectin-9, for the potential treatment of solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer and cholangiocarcinoma, that are difficult to treat and have poor survival rates.
Preclinical | Solid tumors | >50K/year U.S. (Metastatic CRC) |
LYT-210 is a fully human IgG1 mAb directed against the δ1 chain of T cells bearing γδT cell receptors (TCRs) we are designing for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).
Preclinical | Neurological indications |
LYT-300 is an oral form of FDA-approved allopregnanolone, a natural neurosteroid, that may be applicable to a range of neurological conditions.
| Phase completed | Phase in progress | Registration-enabling studies planned |
1. Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection.
The BIG Idea - Moving medicine forward at PureTech
